Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 4/20 | 0.44 |
| ▸ | MMP1 | P03956 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP14 | P50281 | 1/20 | 0.33 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 3/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3203643 | 0.80 | MMP13 (0.39) | MMP13MMP1ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL2448610 | 0.80 | PSIP1 (0.56) | MMP13MMP1ALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL6825821 | 0.78 | ALDH1A1 (0.64) | MMP13MMP1ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL1960675 | 0.78 | ALDH1A1 (0.42) | MMP13ALDH1A1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL22404412 | 0.77 | GAA (0.47) | MMP13MMP1ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL29296547 | 0.77 | NPC1 (0.49) | MMP13MMP1ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL10258225 | 0.77 | PLCG1 (0.55) | MMP13MMP1ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL4014240 | 0.77 | KMT2A (0.47) | MMP13MMP1ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL29297466 | 0.77 | MAPT (0.46) | MMP13MMP1ALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL29296587 | 0.76 | CA2 (0.50) | MMP13MMP1ALDH1A1CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678907-B2 | Halogenation of rylen-carboximides with elementary halogen in a two-phase mixture comprising an organic solvent and water, wherein formed halogen hydroxide is continuously removable from the organic solvent | BASF AKTIENGESSELLSCHAFT (DE) | 2010-03-16 | — | — | US | disclosed |
| EP-1802622-B1 | HALOGENATION OF RYLEN-CARBOXIMIDES WITH ELEMENTARY HALOGEN IN A TWO-PHASE MIXTURE COMPRISING AN ORGANIC SOLVENT AND WATER, WHEREIN FORMED HALOGEN HYDROCIDE IS CONTINUOUSLY REMOVABLE FROM THE ORGANIC SOLVENT | BASF SE (DE) | 2008-04-23 | — | — | EP | disclosed |
| US-20080058526-A1 | Halogenation of Rylen-Carboximides with Elementary Halogene in a Two-Phase Mixture Comprising an Organic Solvent and Water, Wherein Formed Halogene Hydrocide is Continously Removable from the Organic Solvent | BASF AKTIENGESELLSCHAFT (DE) | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058526-A1 | Halogenation of Rylen-Carboximides with Elementary Halogene in a Two-Phase Mixture Comprising an Organic Solvent and Water, Wherein Formed Halogene Hydrocide is Continously Removable from the Organic Solvent | CYP8B1, HACL2, CTRB2 | MMP13 961/4885MMP1 82/4885ALDH1A1 1379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.